Subcutaneous nodule at the vaccine injection site – A case of mistaken identity

Vaccine ◽  
2021 ◽  
Vol 39 (40) ◽  
pp. 6013-6014
Author(s):  
Rowena Silcock ◽  
Ali Moghimi ◽  
Kirsten Perrett ◽  
Nigel Crawford
2006 ◽  
Vol 38 (10) ◽  
pp. 920-921 ◽  
Author(s):  
Véronique Hentgen ◽  
Robert Cohen ◽  
Claire-Anne Siegrist

2019 ◽  
Vol 26 (6) ◽  
Author(s):  
Kate M Edwards ◽  
Robert Booy

2009 ◽  
Vol 26 (4) ◽  
pp. 481-482 ◽  
Author(s):  
MOSHE BEN-SHOSHAN ◽  
CHRISTINE LEJTENYI ◽  
MARIE-NOËL PRIMEAU

2012 ◽  
Vol 190 (2) ◽  
pp. 613-620 ◽  
Author(s):  
John R. Ohlfest ◽  
Brian M. Andersen ◽  
Adam J. Litterman ◽  
Junzhe Xia ◽  
Christopher A. Pennell ◽  
...  

2021 ◽  
Vol 14 (8) ◽  
pp. 762
Author(s):  
Giorgio Treglia ◽  
Marco Cuzzocrea ◽  
Luca Giovanella ◽  
Luigia Elzi ◽  
Barbara Muoio

Recently, several articles reported incidental findings at 2-[18F]FDG PET/CT in patients who have received COVID-19 vaccinations, including hypermetabolic axillary lymph nodes (HALNs) ipsilateral to the COVID-19 vaccine injection site which may cause diagnostic dilemmas. The aim of our work was to calculate the prevalence of this finding. A comprehensive computer literature search of PubMed/MEDLINE, Embase, and Cochrane library databases was performed to identify recently published articles that investigated the prevalence of HALNs detected by 2-[18F]FDG PET/CT after COVID-19 vaccination. Pooled prevalence of this finding was calculated through a meta-analytic approach. Nine recently published articles including 2354 patients undergoing 2-[18F]FDG PET/CT after recent COVID-19 vaccination have been included in the systematic review. Overall, HALNs ipsilateral to the vaccine injection site were frequent findings mainly due to vaccine-related immune response in most of the cases. The pooled prevalence of HALNs after COVID-19 vaccination was 37% (95% confidence interval: 27–47%) but with significant heterogeneity among the included studies. Physicians must be aware and recognize the significant frequency of HALNs at 2-[18F]FDG PET/CT related to immune response to vaccine injection. Larger studies are needed to confirm the findings of this systematic review and meta-analysis.


2021 ◽  
Vol 26 (10) ◽  
Author(s):  
María Fernández-Prada ◽  
Irene Rivero-Calle ◽  
Ana Calvache-González ◽  
Federico Martinón-Torres

Monitoring adverse reactions following immunisation is essential, particularly for new vaccines such as those against COVID-19. We describe 20 cases of acute onset of a single supraclavicular lymphadenopathy manifesting between 24 h and 9 days after ipsilateral intramuscular administration of an mRNA-based COVID-19 vaccine, referred to our WHO Collaborating Centre for Vaccine Safety. Our results indicate that the swelling of supraclavicular lymph nodes following immunisation may constitute a benign and self-limited condition, related to a higher than recommended injection site.


2019 ◽  
Vol 18 (3) ◽  
pp. 175-179 ◽  
Author(s):  
Oxana V. Solonina ◽  
Tatiana M. Sy

Background. Acceptability of routine immunization with vaccine to meningococcus serogroups A, C, W, Y in Russian children have not been studied earlier. Objective. The aim of the study was to understand the safety of polyvalent meningococcal conjugate vaccine administration in two years old children in actual clinical practice. Methods. The vaccination of two years old children against meningococcal disease has been performing in Sakhalin region since April 2018. All children who received single 4-valent meningococcal conjugate vaccine to A, C, W, Y serogroups in the period from April to November 2018 were included into the research. The vaccine safety in general group was estimated by local pediatricians visiting due to general and local adverse effects on vaccine injection in one month period. Safety study for children vaccinated in the period from September to October 2018 was carried out by questioning parents. Results. 1250 children were vaccinated during this research. Local paediatricians has recorded 11 (0.9%) appointments due to adverse effects within 1 month after vaccination. All of them were mild: infiltrates in the vaccine injection site (4 cases), high temperature up to 38°C (7 cases). Survey of 100 parents has shown that at least one adverse effect in 4 weeks period was noted only in 23 children: local reactions (induration, redness at the injection site) in 14 cases, general reactions (temperature increase up to 38.7°C) in 9 cases. No adverse effects needed medical intervention. Conclusion. Adverse effects were recorded in less than 1% of all cases according to local paediatricians appointments and in every 4th case according to parents questioning among all two years old children who undergone immunization with 4-valent meningococcal conjugate vaccine to A, C, W, Y serogroups.


2021 ◽  
Author(s):  
Yaser Al-Worafi ◽  
Long Ming ◽  
Wafa Alseragi ◽  
Abdullah Dhabali ◽  
Abdulkareem Al-Shami

Abstract This study explored the adverse reactions/effects prevalence, types, duration, and severity of inactivated novel coronavirus pneumonia (COVID-19) vaccine among adult frontline health care professionals and educators. A total of A total of 49 frontline workers in Fujairah, UAE (37 health care professionals and 12 educators) were interviewed over a period of three months. All participants were reported that they experienced at least one adverse reaction/effect. The range of COVID-19 vaccine adverse reactions/effects were one to three adverse effects Pain at the vaccine injection site reported by 49 out of 49 participants; swelling/redness of the vaccine injection site reported by 45 out of 49; fatigue reported by 19 out of 49; headache reported by eight; fever reported by one participant. Majority of the reported adverse reactions were described as moderate or mild and the duration was between one day and one week.


Sign in / Sign up

Export Citation Format

Share Document